You should consult your GP or healthcare provider if: You are considering treatment for weight management and have a body mass index (BMI) 30 kg/m, or 27 kg/m with weight-related comorbidities (note that NHS eligibility criteria may differ from the licensed indication, and lower BMI thresholds may apply for some ethnic groups) You have type 2 diabetes and are exploring treatment options for glycaemic control and weight management You are currently taking tirzepatide and experience persistent or severe side effects, particularly gastrointestinal symptoms that interfere with nutrition or hydration You develop severe abdominal pain, which may indicate pancreatitis or gallbladder disease You experience symptoms of hypoglycaemia (shakiness, confusion, sweating, rapid heartbeat) You are taking tirzepatide and planning to start or modify an intensive training programme You have concerns about muscle loss or declining athletic performance while on treatment You are using hormonal contraceptives, as additional contraceptive methods are needed for 4 weeks after starting tirzepatide and after each dose increase You are planning pregnancy (tirzepatide should be discontinued at least 1 month before a planned pregnancy) Important safety considerations: Tirzepatide should be used with caution in individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 It should be used with caution in those with a history of pancreatitis or gallbladder disease Dose adjustments of insulin or sulfonylureas may be needed to reduce hypoglycaemia risk when starting tirzepatide Tirzepatide is not recommended during pregnancy or breastfeeding Regular monitoring of weight, body composition, and metabolic parameters is advisable Healthcare professionals can provide evidence-based guidance on appropriate weight management strategies for athletes, including nutritional counselling, training optimisation, and, where clinically indicated, pharmacological support
Crowley K, Scanaill P, Hermanides J, et al
How Does Retatrutide Purity Relate to Proper Storage Temperature
It works by activating melanocortin receptors in the brain, specifically MC4R (melanocortin-4 receptor)
Pancreatic fibroblast growth factor 21 protects against type 2 diabetes in mice by promoting insulin expression and secretion in a PI3K/Akt signaling-dependent manner
Hair shedding can occur during rapid weight loss or reduced nutrient intake, but other causes such as thyroid disease, iron deficiency, illness, stress, and hereditary hair loss must also be considered
